No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OCGN240517P1500
- 0.03
- 0.000.00%
15min DelayClose May 17 15:50 ET
0.03High0.03Low
0.03Open0.03Pre Close2 Volume5.46K Open Interest1.50Strike Price6.00Turnover840.27%IV-23.04%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.03Time Value100Contract SizeAmericanOptions Type-0.1234Delta0.4606Gamma63.67Leverage Ratio-0.1620Theta0.0000Rho-7.85Eff Leverage0.0001Vega
Intraday
- 5D
- 1D
News
DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 10 points on Friday.Shares of DXC Technology Company (NYSE:DXC) fell sharply in today's pre-market trading afte
Nayax Posts Weak Q1 Results, Joins GameStop, Iris Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Thursday.Shares of Nayax Ltd. (NASDAQ:NYAX) fell sharply in today's pre-market trading following weak
Ocugen Is Maintained at Buy by Chardan Capital
Ocugen Is Maintained at Buy by Chardan Capital
4 Analysts Assess Ocugen: What You Need To Know
4 analysts have expressed a variety of opinions on Ocugen (NASDAQ:OCGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their recent rating
Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study
Ocugen (OCGN) said Wednesday it has completed dosing of the second group of its phase 1/2 clinical study of its experimental gene modifier therapy candidate OCU41OST, being developed as a one-time tre
Express News | HC Wainwright & Co. Reiterates Buy on Ocugen, Maintains $7 Price Target
Comments
$Ocugen (OCGN.US)$ This stock will double to $4 on the next press releases, it will happen at any moment. They have several drugs in stage 3, and several Covid19 medications coming to market.
The average anylyst price target on this stock is $9, with a high target of $25 and a low of $7
The average anylyst price target on this stock is $9, with a high target of $25 and a low of $7
6
1
$Ocugen(OCGN.US$ is still my all time favourite, march towards $2 today lesgooo 🩵
5
3
$Ocugen(OCGN.US$ New stock alert! Bio technology stock. This one will rise 500% over the next few months. Several drugs in stage 3.
Buy OCGN stock upgraded to buy and price target raised to $10.50
Buy OCGN stock upgraded to buy and price target raised to $10.50
6
1
$Meta Platforms(META.US$ $Apple(AAPL.US$ $Ocugen(OCGN.US$ $SINKUNG(0305.MY$
I may not be there yet, but I'm closer than I was yesterday, slowly but surely
#hustling
I may not be there yet, but I'm closer than I was yesterday, slowly but surely
#hustling
16
3
$Ocugen(OCGN.US$ lfgggg
Read more
OptionsKingOP : they have 50 million shares to cover today's volume of 4 million...this will gap and run hard. Over 20% short and no sellers at $1.93